Association of C-reactive protein with high disease activity in systemic sclerosis: results from the Canadian Scleroderma Research Group.
about
Targeted Therapy in Systemic SclerosisHigh serum sCD163/sTWEAK ratio is associated with lower risk of digital ulcers but more severe skin disease in patients with systemic sclerosis.Serum amyloid A is a marker for pulmonary involvement in systemic sclerosis.Does C-reactive protein predict the long-term progression of interstitial lung disease and survival in patients with early systemic sclerosis?The association of low complement with disease activity in systemic sclerosis: a prospective cohort study.Treatment of Rapidly Progressive Systemic Sclerosis: Current and Futures PerspectivesSialic acid level reflects the disturbances of glycosylation and acute-phase reaction in rheumatic diseases.Circulating biomarkers of interstitial lung disease in systemic sclerosis.Current status of systemic sclerosis biomarkers: applications for diagnosis, management and drug development.Molecular biomarkers in interstitial lung diseases.Update on juvenile systemic sclerosis.Facts and promises on lung biomarkers in interstitial lung diseases.Serum prealbumin as an effective prognostic indicator for determining clinical status and prognosis in patients with hemorrhagic strokeRisk factors for severity and manifestations in systemic sclerosis and prediction of disease course.Clinical Trial Design Issues in Systemic Sclerosis: an Update.Membrane array and multiplex bead analysis of tear cytokines in systemic sclerosis.Serum amyloid A induces interleukin-6 in dermal fibroblasts via Toll-like receptor 2, interleukin-1 receptor-associated kinase 4 and nuclear factor-κB.Cardiac tamponade and severe pericardial effusion in systemic sclerosis: report of nine patients and review of the literature.Proteomic Analysis of Sera from Individuals with Diffuse Cutaneous Systemic Sclerosis Reveals a Multianalyte Signature Associated with Clinical Improvement during Imatinib Mesylate Treatment.The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index.Serum prealbumin is an independent predictor of mortality in systemic sclerosis outpatients.Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate).Interstitial lung disease in South Africans with systemic sclerosis.The role of microRNA-5196 in the pathogenesis of systemic sclerosis.Factors associated with the 6-minute walk distance in patients with systemic sclerosis.Unmet Needs in Systemic Sclerosis Understanding and Treatment: the Knowledge Gaps from a Scientist's, Clinician's, and Patient's Perspective.Serum Soluble Vascular Cell Adhesion Molecule-1 Overexpression Is a Disease Marker in Patients with First-Time Diagnosed Antinuclear Antibodies: A Prospective, Observational Pilot Study.Clinical efficacy and safety of bathing with Chinese medicine Taohong Siwu Decoction () for treatment of diffuse cutaneous systemic sclerosis: A randomized, placebo-controlled trial.CD81 and CD48 show different expression on blood eosinophils in systemic sclerosis: new markers for disease and pulmonary inflammation?The correlation between miR-200c and the severity of interstitial lung disease associated with different connective tissue diseases.
P2860
Q28072943-FEDC469A-CF03-4988-8CFD-A750C317D3B8Q33765551-EF91803D-D637-4E7F-B2F2-ED3DC82ECDE8Q35064030-BFC87686-02D9-4BC5-990A-AD6D49F89275Q37276787-C335B44B-14C1-4C86-9F8C-24D95E292E1DQ37358952-B188C89B-BDAC-4F19-B7FC-1919FE42129BQ37381549-9F6EEFD4-B626-4E81-977D-6C8931550273Q37586575-92806077-B410-40F5-9F5F-E85D76B66522Q38044387-CF8419A2-E216-4874-9288-08711E181957Q38156227-945D20E9-304A-4F67-BA22-0BFF96359797Q38220769-67A8ADDD-2EC7-4DAD-9396-046D3F77E07FQ38374314-D2FD32F2-B075-443D-88C3-F09BFAACF766Q38543042-E1F529D3-3F5C-46B1-AEDA-ED003EC025B9Q38602876-3354DB92-4964-40A7-B23C-DA3F359AEC95Q38630663-A3AD667C-4D90-4740-B09F-2084EFC4C79AQ38825869-BC1CA28B-2474-4C49-83BA-7F583891BF67Q38930001-D8D3D333-C99D-46E2-ABB4-77980659D8B0Q39029262-ADCB5C9C-BDE4-4FFE-BA38-D1919049B1BFQ39036353-4BE5421B-0F19-4FAE-BDB1-812FCFC18F1CQ40292542-3770FFA4-7063-422F-B1AB-11517AE1AF03Q40404296-37980547-8097-4DAF-8E28-8535358B4F5FQ40550651-1644C17D-46F5-4274-82C2-1E23C0EA5290Q42698900-F93EE53A-D807-4FE7-8C42-235D9D119633Q46176565-FA702A4A-7759-413C-BD5C-626EF74835CDQ46346274-26A9940A-5B90-4DC3-84E8-CF736B04EF8DQ47151670-4E3182E0-26A4-40C3-B64E-00422B554AF3Q50230077-45101381-33DF-43A9-886C-ED685F0ADAE6Q50329525-B8C84E85-94B4-4CC0-BF16-5EE76839C616Q51137555-0365CC67-87A0-48A7-9067-7ECF68A23E60Q51543475-0E62A52B-241A-4456-9864-679127C66B45Q51700184-7B380FF5-70F9-405E-BE5C-09E40A8DA19E
P2860
Association of C-reactive protein with high disease activity in systemic sclerosis: results from the Canadian Scleroderma Research Group.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Association of C-reactive prot ...... an Scleroderma Research Group.
@en
Association of C-reactive prot ...... an Scleroderma Research Group.
@nl
type
label
Association of C-reactive prot ...... an Scleroderma Research Group.
@en
Association of C-reactive prot ...... an Scleroderma Research Group.
@nl
prefLabel
Association of C-reactive prot ...... an Scleroderma Research Group.
@en
Association of C-reactive prot ...... an Scleroderma Research Group.
@nl
P2093
P2860
P356
P1476
Association of C-reactive prot ...... an Scleroderma Research Group.
@en
P2093
Ashley Bonner
Canadian Scleroderma Research group
Chayawee Muangchan
Janet Pope
Murray Baron
Sarah Harding
Sarit Khimdas
P2860
P304
P356
10.1002/ACR.21716
P577
2012-09-01T00:00:00Z